Text resize

COUNTRY

ASPREE AUS

Phone Icon

1800 728 745

ASPirin in Reducing Events in the Elderly 
FOR PARTICIPANTS
FOR RESEARCHERS
FOR CLINICIANS

NHMRC Funding Boost for Australia’s Largest Clinical Aspirin Trial

Dec 6, 2016

Australian Government funding for ASPREE Completion

 

The ASPREE Clinical Trial received more than $5.5 million in the latest round of National Health and Medical Research Council (NHMRC) grants announced by Minister for Health and Aged Care, Hon Sussan Ley, at Monash University on 3rd December 2016.

 

Grey haired, man in a suit is talking in front of TV microphones next to a women dressed in a dark suit. They stand in front of NHMRC and Monash University banners
ASPREE Principal Investigator, Prof John McNeil (above) with the Minister for Health and Aged Care, the Hon Sussan Ley after announcing $4.7 million of federal funding to complete the ASPREE study.

The ASPREE Completion Project and an aspirin in prevention of colorectal cancer study made the top five highest Monash University NHMRC funded projects.

Both grants will enable ASPREE to answer important questions about the effect of aspirin on disease prevention, including the long-term effect of aspirin or colorectal (bowel) cancer, in older adults.

ASPREE is the first primary prevention trial in the world to weigh the potential benefits versus the risks of daily low-dose (100 mg) aspirin in healthy older adults.

Colorectal cancer (CRC) remains the second most common type of cancer in Australia, with over 17,070 new cases diagnosed and 4,110 deaths recorded in 2015.

Updated 23.04.2021

Other Articles

CliniciansNHMRC Funding Boost for Australia’s Largest Clinical Aspirin Trial